ML-4 POLICY CHANGE TO PCNSL TREATMENT LED BY HEMATOLOGY, AND INITIAL TREATMENT RESULTS

Abstract

Abstract In the treatment of PCNSL, chemotherapy is becoming the main treatment, in a while, radiation therapy is becoming to be avoided. In our hospital, hematology leads an initiative to the treatment of PCNSL from 2021. During the 7 years from 2016, there were 32 cases of PCNSL that underwent initial treatment at our hospital, of which 8 cases occurred after 2021. The breakdown was 6:2 male to female, and the average age was 71.3 years. In 5 relatively young patients, remission was induced with 5 to 6 courses of R-MPV therapy, 3 of which received high-dose chemotherapy combined with autologous peripheral blood stem cell transfusion, all of whom avoided RT and have maintained remission. In 3 older patients, only RT was performed in 1 and HD-MTX therapy was performed in 2, of which RT was combined in 1 and BSC was introduced due to treatment related sepsis in another patient. Although the follow-up period was short, there has been no recurrence except for one patient who became BSC. On the other hand, in 24 patients before 2020, HD-MTX therapy combined with RT was performed in all patients, except for 1 patient who underwent RT only due to advanced age and 1 patient who died before treatment due to poor general condition. Recurrence was observed in 8 cases, and additional RT and chemotherapy were performed. Although no recurrence was seen in 16 cases, there are only 4 patients who had been still followed up, 6 died, and 6 had unknown or BSC, with a poor prognosis. One of the reasons was thought to be related to the decrease in ADL due to radiation injury. In the absence of recurrence, ADL may be maintained long-term in young patients. On the other hand, elderly people cannot avoid RT, which is still a problem.